UY32236A - Compuestos de arilo sustituidos y su uso - Google Patents

Compuestos de arilo sustituidos y su uso

Info

Publication number
UY32236A
UY32236A UY0001032236A UY32236A UY32236A UY 32236 A UY32236 A UY 32236A UY 0001032236 A UY0001032236 A UY 0001032236A UY 32236 A UY32236 A UY 32236A UY 32236 A UY32236 A UY 32236A
Authority
UY
Uruguay
Prior art keywords
diseases
prevention
treatment
compounds
substituted
Prior art date
Application number
UY0001032236A
Other languages
English (en)
Inventor
Beck Dr Hartmut
Ellinghaus Dr Peter
Haerter Dr Michael
Berhoerster Dr Kerstin
Greschat Dr Susanne
Thierauch Dr Karl-Heinz
Suebmeier Frank
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102008057364A external-priority patent/DE102008057364A1/de
Priority claimed from DE102009041241A external-priority patent/DE102009041241A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32236A publication Critical patent/UY32236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere a compuestos de arilo sustituidos, a procedimientos para su preparación. a su uso para tratamiento y/o prevención de enfermedades y a su uso para la preparación de medicamentos para el tratamiento y/o prevención de enfermedades, en particular para tratamiento y/o prevención de enfermedades hiperproliferativas y angiogénicas y para aquellas enfermedades que surgen de la adaptación metabólica de estados hipóxicos. Tales tratamientos se pueden llevar a cabo como monoterapia también en combinación con otros medicamentos o medidas terapéuticas adicionales.
UY0001032236A 2008-11-14 2009-11-11 Compuestos de arilo sustituidos y su uso UY32236A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008057364A DE102008057364A1 (de) 2008-11-14 2008-11-14 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A DE102009041241A1 (de) 2009-09-11 2009-09-11 Substituierte Aryl-Verbindungen und ihre Verwendung

Publications (1)

Publication Number Publication Date
UY32236A true UY32236A (es) 2010-06-30

Family

ID=41403126

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032236A UY32236A (es) 2008-11-14 2009-11-11 Compuestos de arilo sustituidos y su uso

Country Status (14)

Country Link
US (1) US20110301122A1 (es)
EP (1) EP2356112A1 (es)
KR (1) KR20110082570A (es)
CN (1) CN102282142A (es)
AR (1) AR074337A1 (es)
AU (1) AU2009315930A1 (es)
CA (1) CA2743424A1 (es)
IL (1) IL212174A0 (es)
MX (1) MX2011004779A (es)
RU (1) RU2011123672A (es)
TW (1) TW201029998A (es)
UY (1) UY32236A (es)
WO (1) WO2010054764A1 (es)
ZA (1) ZA201103444B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5727002B2 (ja) * 2010-05-08 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換ヘテロサイクリルベンジルピラゾール類およびその使用
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
WO2013057101A1 (de) 2011-10-17 2013-04-25 Bayer Intellectual Property Gmbh Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
JP6453218B2 (ja) * 2012-08-24 2019-01-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を治療するためのｈｉｆ活性の複素環式修飾物質
US9115120B2 (en) 2012-08-24 2015-08-25 Board Of Regents, The University Of Texas Systems Heterocyclic modulators of HIF activity for treatment of disease
JPWO2015060368A1 (ja) * 2013-10-23 2017-03-09 武田薬品工業株式会社 複素環化合物
US9663504B2 (en) 2014-02-25 2017-05-30 Board Of Regents, The University Of Texas System Salts of heterocyclic modulators of HIF activity for treatment of disease
EP3156397B1 (en) 2014-06-13 2019-08-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
EP3015459A1 (en) * 2014-10-30 2016-05-04 Sanofi Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof
EP3713644B1 (en) 2017-11-20 2024-08-07 University of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2a to improve muscle generation and repair
MX2020007565A (es) * 2018-01-30 2020-09-03 Pi Industries Ltd Nuevos oxadiazoles.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4499721B2 (ja) * 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
WO2007065010A2 (en) * 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
US8796253B2 (en) * 2007-05-18 2014-08-05 Bayer Intellectual Property Gmbh Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Also Published As

Publication number Publication date
KR20110082570A (ko) 2011-07-19
EP2356112A1 (de) 2011-08-17
ZA201103444B (en) 2012-07-25
TW201029998A (en) 2010-08-16
MX2011004779A (es) 2011-05-30
RU2011123672A (ru) 2012-12-20
AU2009315930A1 (en) 2010-05-20
CA2743424A1 (en) 2010-05-20
WO2010054764A1 (de) 2010-05-20
IL212174A0 (en) 2011-06-30
CN102282142A (zh) 2011-12-14
AR074337A1 (es) 2011-01-12
US20110301122A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
UY32236A (es) Compuestos de arilo sustituidos y su uso
UY32237A (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
BR112013027119A8 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
CU20120157A7 (es) Heterociclilbencilpirazoles sustituidos y uso de los mismos
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
UY32497A (es) "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso"
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
IL251543A0 (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
BR112012028652A2 (pt) hidroxialquilbenzilpirazois e seu uso
UA103784C2 (ru) Гетероциклически замещенные арильные соединения как ингибиторы гиф
CU20150047A7 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas
UA56015U (ru) Применение производных глюкозамина в качестве церебропротекторного средства

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127